Background
The human KCNA5 gene encodes the pore-forming subunit of a voltage-gated potassium channel. Kv1.5 channels expressed in heart mediate the ultra-rapid delayed rectifier potassium current, IKur, and are potential therapeutic targets in treatment of atrial fibrillation.
| General Info | |
| Product Description | Human Kv1.5 ion channel-expressing, division-arrested cells. |
|---|---|
| Target Type | Ion Channel |
| Product Type | EZCells™ TT |
| Family | Potassium, Voltage-Gated |
| Sub-Type | Kv1.5 |
| Class | Voltage-gated potassium channel |
| Therapeutic Area | cancer, cardiac, neurodegeneration & stroke, pain & inflammation, pulmonary-respiratory, vascular |
| Related Services | Cardiac Ion Channel Panel™, Ion Channel Trafficking Assays |
| Gene Name | KCNA5 |
| Validated Assay/Platform | manual patch clamp |
| References | Gutman GA, et al. 2005. Pharmacol Rev. 57:473-508. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. |
| EZCell Info | |
| Host cell | CHO-K1 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Growth media | Ham’s F12; 10% FBS |
| Growth characteristics | cells remain viable 1–2 days post-thaw |
| Functional expression | mean K+ current amplitude ± SEM = 2.47 ± 1.11 nA (n = 5 cells) at +20 mV |
| Storage and Packaging | |
| Packaging | Cryopreserved irradiated cells, 6x106 cells/vial |
| Storage Recommendation | liquid nitrogen |
| Quantity | 6 million cells |
| Media | |
| Specification Sheet | |



